Clinical research progression in chemoradiation therapy for resectable gastric cancer.
- Author:
Ping WAN
1
;
Min YAN
;
Chao YAN
;
Ren-da BI
;
Chen LI
Author Information
1. Department of Surgery, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Publication Type:Journal Article
- MeSH:
Chemotherapy, Adjuvant;
Clinical Trials, Phase III as Topic;
Combined Modality Therapy;
Humans;
Perioperative Care;
Radiotherapy, Adjuvant;
Randomized Controlled Trials as Topic;
Stomach Neoplasms;
drug therapy;
radiotherapy;
surgery
- From:
Chinese Journal of Gastrointestinal Surgery
2012;15(2):193-196
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, based on the phase III clinical study, postoperative chemoradiation, perioperative chemotherapy with ECF regimen and postoperative adjuvant chemotherapy with oral S-1 have become the standard adjuvant treatment of resectable gastric adenocarcinoma in the United States, Europe, and Japan, respectively. Since the Southwest Oncology Group in 2001 reported a large phase III randomized clinical trial INT0116, adjuvant chemoradiotherapy has become a standard treatment for gastric adenocarcinoma. With the rapid development of chemoradiotherapy technique, clinical researches for using operation combined with chemoradiotherapy to treat gastric adenocarcinoma emerged one after another, including adjuvant postoperative chemoradiation, preoperative chemoradiation, and chemoradiation combined with intraoperative radiotherapy and so on. This review will summarize the recent treatment protocol using chemoradiotherapy for resectable gastric adenocarcinoma, and comprehensively evaluate the clinical value and significance of chemoradiotherapy for resectable gastric adenocarcinoma.
